Phospho-PRKCA (Tyr658) Antibody

說明書

中文名稱：

磷酸化-PRKCA (Tyr658)兔多克隆抗體
貨號(hào)：

CSB-PA060190
規(guī)格：

￥2454
圖片：
Western blot analysis of extracts from COLO205 cells using PKC α (Phospho-Tyr658) Antibody.The lane on the right is treated with the antigen-specific peptide.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) PRKCA Polyclonal antibody
Uniprot No.：

P17252
基因名：

PRKCA
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Peptide sequence around phosphorylation site of tyrosine 658(F-S-Y(p)-V-N) derived from Human PKC ?.
免疫原種屬：

Homo sapiens (Human)
克隆類型：

Polyclonal
純化方式：

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
濃度：

It differs from different batches. Please contact us to confirm it.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:1000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser-52' facilitating its ubiquitination and proteosomal degradation.
基因功能參考文獻(xiàn)：
1. D463H mutation highly specific to chordoid glioma, enhances proliferation of astrocytes and tanycytes PMID: 29915258
2. Modeling of the different conformations of PRKACA-DNAJB1 Chimeric Kinase revealed no obvious steric interactions of the J-domain with the rest of the RIIbeta holoenzyme. PMID: 29335433
3. PKC activation triggers down-regulation of Kv1.3 by inducing a clathrin-mediated endocytic event that targets the channel to lysosomal-degradative compartments. PMID: 28186199
4. Protein kinase C acts as a tumor suppressor.Cancer-associated mutations in protein kinase C are generally loss-of-function mutations.[review] PMID: 28476658
5. results could not only better explain the role of PI-PLCbeta1/PKC-alpha signaling in erythropoiesis but also lead to a better comprehension of the lenalidomide effect on del(5q) MDS and pave the way to innovative, targeted therapies. PMID: 28970249
6. A characteristic di-leucine motif (SVRPLL) in the C-terminal cytoplasmic region of ATP11C becomes functional upon PKCalpha activation. Moreover, endocytosis of ATP11C is induced by Ca(2+)-signaling via Gq-coupled receptors. PMID: 29123098
7. The haplotype carrying rs9909004 influences PRKCA expression in the heart and is associated with traits linked to heart failure, potentially affecting therapy of heart failure PMID: 28120175
8. our results demonstrate that Pc-induced expression of HO-1 is mediated by the PKCA-Nrf-2/HO-1 pathway, and inhibits UVB-induced apoptotic cell death in primary skin cells. PMID: 29470442
9. Regulation of vascular smooth muscle cell calcification by syndecan-4/FGF-2/PKCalpha signalling and cross-talk with TGF-beta1. PMID: 29016732
10. this study reveals a protective role for miR-706 by blocking the oxidative stress-induced activation of PKCalpha/TAOK1. Our results further identify a major implication for miR-706 in preventing hepatic fibrogenesis and suggest that miR-706 may be a suitable molecular target for anti-fibrosis therapy. PMID: 27876854
11. We also discuss the contribution of PKC enzymes to pancreatic diseases, including insulin resistance and diabetes mellitus, as well as pancreatitis and the development and progression of pancreatic cancer PMID: 28826907
12. data provided evidence that increased Rack1-mediated upregulation of PKC kinase activity may be responsible for the development of chemoresistance in T-ALL-derived cell line potentially by reducing FEM1b and Apaf-1 level. PMID: 27644318
13. Regulation of insulin exocytosis by calcium-dependent protein kinase C in beta cells has been summarized. (Review) PMID: 29029784
14. these data propose a mechanism where CD82 membrane organization regulates sustained PKCalpha signaling that results in an aggressive leukemia phenotype. These observations suggest that the CD82 scaffold may be a potential therapeutic target for attenuating aberrant signal transduction in acute myeloid leukemia (AML). PMID: 27417454
15. MiR-3148 may play an important role in the development of CTEPH. The key mechanisms for this miRNA may be hsa-miR-3148-AR-pathways in cancer or hsa-miR-3148-PRKCA-pathways in cancer/glioma/ErbB signaling pathway. PMID: 28904974
16. the spatial organization of cPKCs bound to the plasma membrane, is reported. PMID: 27808106
17. PRKCA is a recurrently mutated oncogene in human chordoid glioma. PMID: 29476136
18. Our study showed that PKCalpha modulated cell resistance to apoptosis by stimulating NF-kappaB activation and thus promoted the tumorigenesis of bladder cancer. PMID: 28629334
19. PKCalpha translocation may occur as an early event in radiation-induced bystander responses. PMID: 27165942
20. our study indicated that PKC alpha and beta appeared coping with oncogenic Ras or mutated Akt to maintain the balance of the homeostasis in cancer cells. Once these PKC isoforms were suppressed, the redox state in the cancer cells was disrupted, which elicited persistent oncogenic stress and subsequent apoptotic crisis. PMID: 28415683
21. high expression of both PLCE1 and PRKCA is significantly associated with poor outcomes of the patients with esophageal cancers. PMID: 28402280
22. In nasopharyngeal carcinoma, PKCalpha is linked to the invasion of adjacent tissues, especially in the skull base. Down-regulation of PKCalpha is a risk factor for regional lymph node metastasis. PMID: 28084179
23. LAV-BPIFB4 isoform modulates eNOS signalling through Ca2+/PKC-alpha-dependent mechanism. PMID: 28419216
24. Studied interactions between protein kinase C alpha (PKCalpha), FOXC2, and p120-catenin (CTNND1) in breast cancer, cell migration/ invasion; found PKCalpha acts as an upstream regulator of FOXC2, which in turn represses the expression of p120-catenin, in both in endocrine resistant ER+breast cancer and basal A triple negative breast cancer PMID: 29216867
25. Phosphorylated PKCalpha is elevated in epidermis genetically deleted of DLX3 and the hyperproliferative response to TPA is increased, suggesting that the homeobox protein indirectly regulates the activity in the pathway, possibly through an effect on reduced phosphatase expression PMID: 28186503
26. Results show that PKCalpha expression is under the regulation of miR-142-3p contributing to reduced osteoclasts survival. PMID: 27113904
27. Molecular Determinants for the Binding Mode of Alkylphosphocholines in the C2 Domain of PKCalpha. PMID: 27490031
28. Studies suggest that rare deleterious variants of PARD3 in the aPKC-binding region contribute to human cranial neural tube defect (NTD). PMID: 27925688
29. study identified PKCalpha as hepatitis E virus HEV in host defense PMID: 28077314
30. ADP inhibits mesothelioma cell proliferation via PKC-alpha/ERK/p53 signaling. PMID: 28777435
31. This study provides evidences of a new PKCalpha/GAP-43 nuclear signalling pathway that controls neuronal differentiation in Human Periodontal Ligament Stem Cells. PMID: 27478064
32. protein kinase Calpha (PKCalpha) gain of function mutations may promote synaptic defects in Alzheimer's disease PMID: 27165780
33. Some polyphenols exert their antioxidant properties by regulating the transcription of the antioxidant enzyme genes through PKC signaling. Regulation of PKC by polyphenols is isoform dependent PMID: 27369735
34. Data suggest that phosphorylation activity of PRKCA stems from conformational flexibility in region C-terminal to phosphorylated Ser/Thr residues; flexibility of substrate-kinase interaction enables an Arg/Lys two to three amino acids C-terminal to phosphorylated Ser/Thr to prime a catalytically active conformation, facilitating phosphoryl transfer to substrate. PMID: 28821615
35. these results provide evidence for inherent deficits in the cystic fibrosis macrophage oxidative burst caused by decreased phosphorylation of NADPH oxidase cytosolic components that are augmented by Burkholderia PMID: 28093527
36. The interplay between intracellular progesterone receptor and PRKCA-PRKCD plays a key role in migration and invasion of human glioblastoma cells. PMID: 27717886
37. PRKCA SNPs are associated with neuropathic pain post total joint replacement. PMID: 28051079
38. These findings provide the first evidence linking PKC activation to suppression of Kv7 currents, membrane depolarization, and Ca(2+) influx via L-type voltage-sensitive Ca(2+) channels as a mechanism for histamine-induced bronchoconstriction. PMID: 28283479
39. pseudosubstrate and C1a domains, however, are minimally essential for maintaining the inactivated state. Furthermore, disrupting known interactions between the C1a and other regulatory domains releases the autoinhibited interaction and increases basal activity PMID: 28049730
40. In polymorphism PRKCA rs9892651, HDL-C levels were lower in carriers of CC and TC genotypes that were more frequent in current-wheezers Vs TT genotype (52.2 and 52.7 Vs 55.2 mg/dl, p-value = 0.042 and p-value for trend = 0.02). PMID: 27411394
41. Ca(2+)-PKC-MARCKS-PIP2-PI3K-PIP3 system functions as an activation module in vitro PMID: 27119641
42. phosphorylation of TIMAP on Ser331 by PKC represents a new mechanism of endothelial barrier regulation, through the inhibition of phospho-ERM dephosphorylation PMID: 27939168
43. PKCalpha-GSK3beta-NF-kappaB signaling pathway involvement in TRAIL-induced apoptosis PMID: 27219672
44. Curcumin inhibited phorbol ester-induced membrane translocation of protein kinase C-epsilon (PKCepsilon) mutants, in which the epsilonC1 domain was replaced with alphaC1, but not the protein kinase C-alpha (PKCalpha) mutant in which alphaC1 was replaced with the epsilonC1 domain, suggesting that alphaC1 is a determinant for curcumin's inhibitory effect. PMID: 27776404
45. a library of FRET sensors to monitor these transient complexes, specifically examining weak interactions between the catalytic domain of protein kinase Calpha and 14 substrate peptides. PMID: 27555323
46. calpain and protein kinase Calpha abnormal release promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients PMID: 27349634
47. protein kinase C modulates alpha1B-adrenergic receptor transfer to late endosomes and that Rab9 regulates this process and participates in G protein-mediated signaling turn-off. PMID: 28082304
48. Protein kinase C enhances the swelling-induced chloride current in human atrial myocytes. PMID: 27376808
49. these results confirm the correlation between AXL and PKCalpha, and suggest PKCalpha-AXL signaling may be a treatment target, particularly in malignant cancer cells. PMID: 27357025
50. After inhibition of the PKC/ERK signalling pathway, the effects of DOR on breast cancer were significantly attenuated in vivo and in vitro. In summary, DOR is highly expressed in breast cancer and is closely related to its progression. These results suggest that DOR may serve as a potential biomarker for the early diagnosis of breast cancer and may be a viable molecular target for therapeutic intervention. PMID: 27665747
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm. Cell membrane; Peripheral membrane protein. Mitochondrion membrane; Peripheral membrane protein. Nucleus.
蛋白家族：

Protein kinase superfamily, AGC Ser/Thr protein kinase family, PKC subfamily
數(shù)據(jù)庫鏈接：

HGNC: 9393

OMIM: 176960

KEGG: hsa:5578

STRING: 9606.ENSP00000408695

UniGene: Hs.531704

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human